Trial Outcomes & Findings for Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy (NCT NCT05152927)

NCT ID: NCT05152927

Last Updated: 2025-12-15

Results Overview

Median number of frozen sections (or aspirate) sent for analysis during the parathyroidectomy (PTx) procedure to confirm potential parathyroid tissue

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

79 participants

Primary outcome timeframe

At the end of the parathyroidectomy, up to 5 hours

Results posted on

2025-12-15

Participant Flow

Participant milestones

Participant milestones
Measure
Parathyroid Eye (PTeye)
For participants assigned to the study arm, the surgeon will use the PTeye as an intraoperative tool to identify if a suspect tissue is a parathyroid or not, during the parathyroid surgery.
Usual Standard of Care
The surgeon will proceed with the parathyroid surgery as usual, while relying solely on her/his surgical experience in identifying the parathyroid glands during the operations.
Overall Study
STARTED
38
41
Overall Study
COMPLETED
38
41
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Parathyroid Eye (PTeye)
n=38 Participants
For participants assigned to the study arm, the surgeon will use the PTeye as an intraoperative tool to identify if a suspect tissue is a parathyroid or not, during the parathyroid surgery.
Usual Standard of Care
n=41 Participants
The surgeon will proceed with the parathyroid surgery as usual, while relying solely on her/his surgical experience in identifying the parathyroid glands during the operations.
Total
n=79 Participants
Total of all reporting groups
Age, Continuous
68 years
n=9 Participants
64 years
n=32 Participants
67 years
n=18 Participants
Sex: Female, Male
Female
27 Participants
n=9 Participants
30 Participants
n=32 Participants
57 Participants
n=18 Participants
Sex: Female, Male
Male
11 Participants
n=9 Participants
11 Participants
n=32 Participants
22 Participants
n=18 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
1 Participants
n=9 Participants
4 Participants
n=32 Participants
5 Participants
n=18 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
37 Participants
n=9 Participants
36 Participants
n=32 Participants
73 Participants
n=18 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=9 Participants
1 Participants
n=32 Participants
1 Participants
n=18 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=9 Participants
0 Participants
n=32 Participants
0 Participants
n=18 Participants
Race (NIH/OMB)
Asian
4 Participants
n=9 Participants
3 Participants
n=32 Participants
7 Participants
n=18 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
1 Participants
n=9 Participants
1 Participants
n=32 Participants
2 Participants
n=18 Participants
Race (NIH/OMB)
Black or African American
2 Participants
n=9 Participants
2 Participants
n=32 Participants
4 Participants
n=18 Participants
Race (NIH/OMB)
White
27 Participants
n=9 Participants
27 Participants
n=32 Participants
54 Participants
n=18 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=9 Participants
0 Participants
n=32 Participants
0 Participants
n=18 Participants
Race (NIH/OMB)
Unknown or Not Reported
4 Participants
n=9 Participants
8 Participants
n=32 Participants
12 Participants
n=18 Participants
Region of Enrollment
United States
38 participants
n=9 Participants
41 participants
n=32 Participants
79 participants
n=18 Participants

PRIMARY outcome

Timeframe: At the end of the parathyroidectomy, up to 5 hours

Median number of frozen sections (or aspirate) sent for analysis during the parathyroidectomy (PTx) procedure to confirm potential parathyroid tissue

Outcome measures

Outcome measures
Measure
Parathyroid Eye (PTeye)
n=38 Participants
For participants assigned to the study arm, the surgeon will use the PTeye as an intraoperative tool to identify if a suspect tissue is a parathyroid or not, during the parathyroid surgery.
Usual Standard of Care
n=41 Participants
The surgeon will proceed with the parathyroid surgery as usual, while relying solely on her/his surgical experience in identifying the parathyroid glands during the operations.
Median Number of Frozen Sections (or Parathyroid Aspirate) Sent for Analysis
0 frozen aspirate samples
Interval 0.0 to 1.0
0 frozen aspirate samples
Interval 0.0 to 1.0

SECONDARY outcome

Timeframe: 5-14 days after PTx procedure

Failure of intra-operative parathyroid hormone (PTH) to normalize (defined as failure of PTH to drop \> 50% of its baseline value at final intra-operative PTH assay and/or failure of PTH to drop \< 65 pg/ml or 6.9 pmol/L). Participants will be categorized as having persistent hyperparathyroidism (Immediate) Yes or No.

Outcome measures

Outcome measures
Measure
Parathyroid Eye (PTeye)
n=38 Participants
For participants assigned to the study arm, the surgeon will use the PTeye as an intraoperative tool to identify if a suspect tissue is a parathyroid or not, during the parathyroid surgery.
Usual Standard of Care
n=41 Participants
The surgeon will proceed with the parathyroid surgery as usual, while relying solely on her/his surgical experience in identifying the parathyroid glands during the operations.
Number of Participants With Persistent Hyperparathyroidism (Immediate)
0 Participants
1 Participants

SECONDARY outcome

Timeframe: 5-14 days after PTx procedure

Population: Participants from both groups were missing labs. Not all PTEye participants returned to the clinic for blood draws within 5-14 days to obtain lab values required to calculate this endpoint and standard clinical care does not necessitate participants returning for labs routinely at each follow-up time points.

Elevated blood calcium levels (total blood calcium level \> 10.5 mg/dL or 2.6 mmol/L) with/without elevated parathyroid hormone (PTH) (serum intact PTH \> 65 pg/ml or 6.9 pmol/L) at first postoperative visit. Participants will be categorized as having persistent hyperparathyroidism or hypercalcemia (transient) Yes or No.

Outcome measures

Outcome measures
Measure
Parathyroid Eye (PTeye)
n=21 Participants
For participants assigned to the study arm, the surgeon will use the PTeye as an intraoperative tool to identify if a suspect tissue is a parathyroid or not, during the parathyroid surgery.
Usual Standard of Care
n=20 Participants
The surgeon will proceed with the parathyroid surgery as usual, while relying solely on her/his surgical experience in identifying the parathyroid glands during the operations.
Number of Participants With Persistent Hyperparathyroidism or Hypercalcemia (Transient)
0 Participants
0 Participants

SECONDARY outcome

Timeframe: Up to 6 months after PTx procedure

Population: Participants from both groups were missing labs. Not all PTEye participants returned to the clinic for blood draws within 5-14 days to obtain lab values required to calculate this endpoint and standard clinical care does not necessitate participants returning for labs routinely at each follow-up time points.

If blood calcium with/without parathyroid hormone (PTH) has not normalized at 1st post-operative visit, calcium and/or PTH is subsequently measured as necessary. Patient is defined to have a failed parathyroidectomy if hypercalcemia/hyperparathyroidism (defined as total blood calcium level \> 10.5 mg/dL or 2.6 mmol/L, with/without elevated serum intact PTH \> 65 pg/ml or 6.9 pmol/L) persists at or after the 6th postoperative month. Participants will be categorized has having persistent hyperparathyroidism or hypercalcemia (failed parathyroidectomy), Yes or No.

Outcome measures

Outcome measures
Measure
Parathyroid Eye (PTeye)
n=29 Participants
For participants assigned to the study arm, the surgeon will use the PTeye as an intraoperative tool to identify if a suspect tissue is a parathyroid or not, during the parathyroid surgery.
Usual Standard of Care
n=33 Participants
The surgeon will proceed with the parathyroid surgery as usual, while relying solely on her/his surgical experience in identifying the parathyroid glands during the operations.
Number of Participants Persistent Hyperparathyroidism or Hypercalcemia (Failed Parathyroidectomy)
0 Participants
1 Participants

SECONDARY outcome

Timeframe: At the end of the parathyroidectomy, up to 5 hours

Overall number of parathyroid glands identified (Combined both the experimental Group (Glands identified with naked eye + NIRAF) and Control Group (Glands identified with naked eye)

Outcome measures

Outcome measures
Measure
Parathyroid Eye (PTeye)
n=38 Participants
For participants assigned to the study arm, the surgeon will use the PTeye as an intraoperative tool to identify if a suspect tissue is a parathyroid or not, during the parathyroid surgery.
Usual Standard of Care
n=41 Participants
The surgeon will proceed with the parathyroid surgery as usual, while relying solely on her/his surgical experience in identifying the parathyroid glands during the operations.
Number of Parathyroid Glands (PG) Identified
45 parathyroid glands
45 parathyroid glands

SECONDARY outcome

Timeframe: At the end of the parathyroidectomy, up to 5 hours

Population: Only 4 participants had glands identified with NIRAF, which was not seen with surgeon's naked eye

Median number of parathyroid glands identified with NIRAF, which was not seen with surgeon's naked eye during bilateral neck explorations (where the surgeon is looking for more than 1 parathyroid gland)

Outcome measures

Outcome measures
Measure
Parathyroid Eye (PTeye)
n=4 Participants
For participants assigned to the study arm, the surgeon will use the PTeye as an intraoperative tool to identify if a suspect tissue is a parathyroid or not, during the parathyroid surgery.
Usual Standard of Care
The surgeon will proceed with the parathyroid surgery as usual, while relying solely on her/his surgical experience in identifying the parathyroid glands during the operations.
Median Number of Parathyroid Glands Identified With NIRAF (PTeye Group Only)
1 parathyroid glands
Interval 1.0 to 2.0

SECONDARY outcome

Timeframe: At the end of the parathyroidectomy, up to 5 hours

Median number of diseased parathyroid glands identified intra-operatively versus glands localized preoperatively using sestamibi, Computerized tomography (CT) or ultrasound

Outcome measures

Outcome measures
Measure
Parathyroid Eye (PTeye)
n=38 Participants
For participants assigned to the study arm, the surgeon will use the PTeye as an intraoperative tool to identify if a suspect tissue is a parathyroid or not, during the parathyroid surgery.
Usual Standard of Care
n=41 Participants
The surgeon will proceed with the parathyroid surgery as usual, while relying solely on her/his surgical experience in identifying the parathyroid glands during the operations.
Median Number of Diseased Parathyroid Glands Identified Versus Preoperatively Localized Glands
Intra-operatively
1 parathyroid glands
Interval 1.0 to 2.0
1 parathyroid glands
Interval 0.0 to 2.0
Median Number of Diseased Parathyroid Glands Identified Versus Preoperatively Localized Glands
Localized pre-operatively
1 parathyroid glands
Interval 1.0 to 3.0
1 parathyroid glands
Interval 1.0 to 3.0

SECONDARY outcome

Timeframe: At the end of the parathyroidectomy, up to 5 hours

The median number of intra-operative parathyroid hormone assays (per person) sent during the procedure to the lab

Outcome measures

Outcome measures
Measure
Parathyroid Eye (PTeye)
n=38 Participants
For participants assigned to the study arm, the surgeon will use the PTeye as an intraoperative tool to identify if a suspect tissue is a parathyroid or not, during the parathyroid surgery.
Usual Standard of Care
n=41 Participants
The surgeon will proceed with the parathyroid surgery as usual, while relying solely on her/his surgical experience in identifying the parathyroid glands during the operations.
Median Number of Intra-operative Parathyroid Hormone (PTH) Assays Sent
5 assays
Interval 4.0 to 8.0
5 assays
Interval 4.0 to 12.0

SECONDARY outcome

Timeframe: During parathyroidectomy, up to 5 hours

Population: Data was not collected for one participant from each group

Median duration in minutes taken to identify 1st parathyroid gland in PTx procedure - timed from skin incision to finding PG

Outcome measures

Outcome measures
Measure
Parathyroid Eye (PTeye)
n=37 Participants
For participants assigned to the study arm, the surgeon will use the PTeye as an intraoperative tool to identify if a suspect tissue is a parathyroid or not, during the parathyroid surgery.
Usual Standard of Care
n=40 Participants
The surgeon will proceed with the parathyroid surgery as usual, while relying solely on her/his surgical experience in identifying the parathyroid glands during the operations.
Median Duration Taken to Identify First Parathyroid Gland
38 minutes
Interval 15.0 to 154.0
31 minutes
Interval 11.0 to 184.0

SECONDARY outcome

Timeframe: At the end of the parathyroidectomy, up to 5 hours

Population: Data was not collected for one participant from each group

Median duration taken to identify last parathyroid gland in PTx procedure - timed from skin incision to finding the last PG

Outcome measures

Outcome measures
Measure
Parathyroid Eye (PTeye)
n=37 Participants
For participants assigned to the study arm, the surgeon will use the PTeye as an intraoperative tool to identify if a suspect tissue is a parathyroid or not, during the parathyroid surgery.
Usual Standard of Care
n=40 Participants
The surgeon will proceed with the parathyroid surgery as usual, while relying solely on her/his surgical experience in identifying the parathyroid glands during the operations.
Median Duration Taken to Identify Last Parathyroid Gland
48 minutes
Interval 16.0 to 224.0
35 minutes
Interval 11.0 to 184.0

SECONDARY outcome

Timeframe: Up to 5 hours

Median duration of PTx procedure - timed from skin incision until the surgeon notifies the anesthesia team to awaken the patient in minutes

Outcome measures

Outcome measures
Measure
Parathyroid Eye (PTeye)
n=38 Participants
For participants assigned to the study arm, the surgeon will use the PTeye as an intraoperative tool to identify if a suspect tissue is a parathyroid or not, during the parathyroid surgery.
Usual Standard of Care
n=41 Participants
The surgeon will proceed with the parathyroid surgery as usual, while relying solely on her/his surgical experience in identifying the parathyroid glands during the operations.
Median Duration of Parathyroidectomy (PTx) Procedure
87 minutes
Interval 34.0 to 243.0
82 minutes
Interval 26.0 to 296.0

SECONDARY outcome

Timeframe: At the end of the parathyroidectomy, up to 5 hours

Median time in minutes taken for PTH to attain cure criteria or normalize - timed from skin incision until the PTH levels drops \> 50% of its baseline value and/or PTH drops \< 65 pg/ml or 6.9 pmol/L

Outcome measures

Outcome measures
Measure
Parathyroid Eye (PTeye)
n=38 Participants
For participants assigned to the study arm, the surgeon will use the PTeye as an intraoperative tool to identify if a suspect tissue is a parathyroid or not, during the parathyroid surgery.
Usual Standard of Care
n=41 Participants
The surgeon will proceed with the parathyroid surgery as usual, while relying solely on her/his surgical experience in identifying the parathyroid glands during the operations.
Median Duration for Intraoperative Parathyroid Hormone (PTH) to Normalize
76 minutes
Interval 27.0 to 243.0
66 minutes
Interval 38.0 to 150.0

SECONDARY outcome

Timeframe: 0-72 hours after PTx procedure

Median number of nights spent in the hospital post-surgery is defined as having spent \<= 23 hours (0 nights) or \> 23 hours (1 night) at the hospital for postoperative recovery after the surgical procedure. Participants who had surgery scheduled for later in the day will be counted as spending one night in the hospital due to the minimum required observation period post-surgery and followed institutional standards for discharge; discharged the next day. Participants who had surgery scheduled for earlier in the day were discharged on the same day of surgery.

Outcome measures

Outcome measures
Measure
Parathyroid Eye (PTeye)
n=38 Participants
For participants assigned to the study arm, the surgeon will use the PTeye as an intraoperative tool to identify if a suspect tissue is a parathyroid or not, during the parathyroid surgery.
Usual Standard of Care
n=40 Participants
The surgeon will proceed with the parathyroid surgery as usual, while relying solely on her/his surgical experience in identifying the parathyroid glands during the operations.
Median Number of Nights in the Hospital After Parathyroidectomy
<= 23 hours
0 number of nights
Interval 0.0 to 0.0
0 number of nights
Interval 0.0 to 0.0
Median Number of Nights in the Hospital After Parathyroidectomy
> 23 hours
1 number of nights
Interval 1.0 to 1.0
1 number of nights
Interval 1.0 to 1.0

SECONDARY outcome

Timeframe: Up to 10 days after PTx procedure

The median number of tissues per person that were excised by surgeon assumed to be parathyroid tissue, but is later validated as non-parathyroid tissue (false positive) by histology

Outcome measures

Outcome measures
Measure
Parathyroid Eye (PTeye)
n=38 Participants
For participants assigned to the study arm, the surgeon will use the PTeye as an intraoperative tool to identify if a suspect tissue is a parathyroid or not, during the parathyroid surgery.
Usual Standard of Care
n=41 Participants
The surgeon will proceed with the parathyroid surgery as usual, while relying solely on her/his surgical experience in identifying the parathyroid glands during the operations.
Median Number of 'False Positive' Tissue Samples Excised by Surgeon
0 tissue samples
Interval 0.0 to 0.0
0 tissue samples
Interval 0.0 to 0.0

SECONDARY outcome

Timeframe: Up to 6 months after PTx procedure

Number of participants who required a doctor visit/emergency department visit and/or hospital admission due to persistent hypercalcemia and/or associated symptoms after the parathyroidectomy procedure will be categorized as binary (yes or no) if any follow-up visits or admissions occurred.

Outcome measures

Outcome measures
Measure
Parathyroid Eye (PTeye)
n=38 Participants
For participants assigned to the study arm, the surgeon will use the PTeye as an intraoperative tool to identify if a suspect tissue is a parathyroid or not, during the parathyroid surgery.
Usual Standard of Care
n=41 Participants
The surgeon will proceed with the parathyroid surgery as usual, while relying solely on her/his surgical experience in identifying the parathyroid glands during the operations.
Number of Participants With Reported Doctor Visits/Emergency Department Visits or Hospital Admissions
5 participants
8 participants

SECONDARY outcome

Timeframe: From 6 - 12 months after PTx procedure

Number of participants with an indication that repeat PTx procedure may need to be performed after the current procedure will be categorized as binary (yes or no)

Outcome measures

Outcome measures
Measure
Parathyroid Eye (PTeye)
n=38 Participants
For participants assigned to the study arm, the surgeon will use the PTeye as an intraoperative tool to identify if a suspect tissue is a parathyroid or not, during the parathyroid surgery.
Usual Standard of Care
n=41 Participants
The surgeon will proceed with the parathyroid surgery as usual, while relying solely on her/his surgical experience in identifying the parathyroid glands during the operations.
Number of Participants Who Have Had Repeat Parathyroidectomy (PTx) Procedure
0 Participants
1 Participants

Adverse Events

Parathyroid Eye (PTeye)

Serious events: 2 serious events
Other events: 0 other events
Deaths: 0 deaths

Usual Standard of Care

Serious events: 5 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
Parathyroid Eye (PTeye)
n=38 participants at risk
For participants assigned to the study arm, the surgeon will use the PTeye as an intraoperative tool to identify if a suspect tissue is a parathyroid or not, during the parathyroid surgery.
Usual Standard of Care
n=41 participants at risk
The surgeon will proceed with the parathyroid surgery as usual, while relying solely on her/his surgical experience in identifying the parathyroid glands during the operations.
Respiratory, thoracic and mediastinal disorders
Pleural effusion
2.6%
1/38 • Number of events 1 • Up to 6 months
0.00%
0/41 • Up to 6 months
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify
0.00%
0/38 • Up to 6 months
2.4%
1/41 • Number of events 1 • Up to 6 months
Injury, poisoning and procedural complications
Fracture
0.00%
0/38 • Up to 6 months
2.4%
1/41 • Number of events 1 • Up to 6 months
Cardiac disorders
Pericardial effusion
0.00%
0/38 • Up to 6 months
2.4%
1/41 • Number of events 1 • Up to 6 months
Nervous system disorders
Syncope
0.00%
0/38 • Up to 6 months
2.4%
1/41 • Number of events 1 • Up to 6 months
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neoplasms benign, malignant and unspecified (incl cysts and polyps), Other - specify
0.00%
0/38 • Up to 6 months
2.4%
1/41 • Number of events 1 • Up to 6 months

Other adverse events

Adverse event data not reported

Additional Information

Dr. Quan-Yang Duh, MD

University of California, San Francisco

Phone: (415) 221-4810

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place